A pharmaceutically acceptable freeze-dried formulation consisting of an amorphous phase and a cryst. phase and
including at least one non-protein active principle is disclosed. The formulation is characterized in that it contains
mannitol and alanine in a ratio R of 0.1-1, where R is the wt. of mannitol over the wt. of alanine. A free-dried
pharmaceutical contained SR 57746A 0.44, alanine 72.0, mannitol 36.0, citric acid 30.8, and Polysorbate-80 4.0 mg.